These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36796937)

  • 1. Lessons from other fields of medicine, Part 2: Cystic fibrosis.
    Vijaykumar K; Rowe SM
    Handb Clin Neurol; 2023; 192():119-130. PubMed ID: 36796937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis.
    Derichs N
    Eur Respir Rev; 2013 Mar; 22(127):58-65. PubMed ID: 23457166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
    Mayer-Hamblett N; Boyle M; VanDevanter D
    Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function.
    Arora K; Naren AP
    Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new era of personalized medicine for cystic fibrosis - at last!
    Quon BS; Wilcox PG
    Can Respir J; 2015; 22(5):257-60. PubMed ID: 26083544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
    Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
    Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.
    Mall MA; Mayer-Hamblett N; Rowe SM
    Am J Respir Crit Care Med; 2020 May; 201(10):1193-1208. PubMed ID: 31860331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evidence-based treatment of cystic fibrosis].
    Ringshausen FC; Hellmuth T; Dittrich AM
    Internist (Berl); 2020 Dec; 61(12):1212-1229. PubMed ID: 33201261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
    Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
    Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystic fibrosis: a model system for precision medicine.
    Martiniano SL; Sagel SD; Zemanick ET
    Curr Opin Pediatr; 2016 Jun; 28(3):312-7. PubMed ID: 27031658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: progress to date.
    Becq F
    Drugs; 2010 Feb; 70(3):241-59. PubMed ID: 20166764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Therapies to Correct the Cystic Fibrosis Basic Defect.
    Bergeron C; Cantin AM
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34201249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CFTR: cystic fibrosis and beyond.
    Mall MA; Hartl D
    Eur Respir J; 2014 Oct; 44(4):1042-54. PubMed ID: 24925916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Applications of Biomarkers and Personalized Medicine in Cystic Fibrosis.
    Guimbellot JS; Nichols DP; Brewington JJ
    Clin Chest Med; 2022 Dec; 43(4):617-630. PubMed ID: 36344070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies.
    Ensinck MM; Carlon MS
    Cells; 2022 Jun; 11(12):. PubMed ID: 35740997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient personalized translational tools in cystic fibrosis to transform data from bench to bed-side and back.
    Arora K; Yang F; Brewington J; McPhail G; Cortez AR; Sundaram N; Ramananda Y; Ogden H; Helmrath M; Clancy JP; Naren AP
    Am J Physiol Gastrointest Liver Physiol; 2021 Jun; 320(6):G1123-G1130. PubMed ID: 33949881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
    Cuyx S; De Boeck K
    Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystic fibrosis precision therapeutics: Emerging considerations.
    Joshi D; Ehrhardt A; Hong JS; Sorscher EJ
    Pediatr Pulmonol; 2019 Nov; 54 Suppl 3(Suppl 3):S13-S17. PubMed ID: 31715091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cystic fibrosis: From gene discovery to precision medicine].
    Férec C
    Med Sci (Paris); 2021; 37(6-7):618-624. PubMed ID: 34180821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.